Nemaura Medical (OTCMKTS:NMRD – Get Free Report) is anticipated to release its resultson Monday, August 10th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $0.20 million for the quarter.
Nemaura Medical Trading Up 9,900.0%
OTCMKTS:NMRD traded up $0.00 on Monday, hitting $0.00. 800 shares of the stock were exchanged, compared to its average volume of 3,367. Nemaura Medical has a 52 week low of $0.00 and a 52 week high of $0.05. The stock has a market capitalization of $4,035.00, a P/E ratio of -0.00 and a beta of 0.46.
Nemaura Medical Company Profile
Nemaura Medical PLC is a medical technology company focused on developing non?invasive monitoring solutions for diabetes management and other metabolic applications. The company’s core offering centers on sugarBEAT, a wearable continuous glucose monitoring (CGM) system designed to provide real-time glucose readings through a disposable skin patch. By eliminating the need for finger-stick testing, Nemaura aims to improve patient comfort and adherence, particularly for individuals managing type 1 and type 2 diabetes.
The sugarBEAT system utilizes a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, enabling glucose measurement without needle penetration.
See Also
- Five stocks we like better than Nemaura Medical
- Large Caps Across Planes, Tech and Oil Announce Over $10 Billion in Buybacks
- A Sweet Beat and a Wearables Rally Came With Reasons to Pause
- 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
